# US 2026/0103696 A1 · Compositions and methods for adoptive cell therapy for cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0103696 A1
- Document ID: US20260103696A1
- Status: Published application
- Kind: A1
- Application number: 19/069,114
- Filed: 2025-03-03
- Published: 2026-04-16
- Earliest claimed: 2017-06-30
- Assignees: Memorial Sloan Kettering Cancer Center
- Applicants: Memorial Sloan Kettering Cancer Center
- Inventors: David A. SCHEINBERG; Thomas J. GARDNER; Derek S. TAN; Jonghan LEE; Ivo LORENZ
- Web page: https://patentgrep.com/patent/US20260103696A1

## CPC

- C12N 9/485: {Exopeptidases (3.4.11-3.4.19)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/7076: containing purines, e.g. adenosine, adenylic acid
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/30: characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/4211: {CD19 or B4}
- A61K 40/4243: {Wilms tumor 1 [WT1]}
- A61K 40/4244: {Enzymes}
- A61K 40/427: {PRAME}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C07D 239/94: Nitrogen atoms
- C07D 501/16: with a double bond between positions 2 and 3
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07H 19/167: with ribosyl as the saccharide radical
- C07K 14/52: Cytokines; Lymphokines; Interferons
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K 16/2803: {against the immunoglobulin superfamily}
- C12N 5/0636: {T lymphocytes}
- C12N 9/0006: {acting on CH-OH groups as donors (1.1)}
- C12N 9/2405: {Glucanases}
- C12N 9/86: acting on amide bonds in cyclic amides, e.g. penicillinase {(3.5.2)}
- C12Y 304/17011: Glutamate carboxypeptidase (3.4.17.11)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2039/804: {Blood cells [leukemia, lymphoma]}
- A61K 2239/25: Suicide switch
- A61K 2239/48: Blood cells, e.g. leukemia or lymphoma
- A61K 2239/49: Breast
- A61K 2239/50: Colon
- A61K 2239/55: Lung
- A61K 2239/59: Reproductive system, e.g. uterus, ovaries, cervix or testes
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2319/02: containing a signal sequence
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C07K 2319/35: containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
- C12N 2501/734: Proteases (EC 3.4.)
- C12N 2510/00: Genetically modified cells
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Y: ENZYMES
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Provided herein are compositions and methods for adoptive cell therapy comprising engineered immune cells that express a tumor antigen-targeted chimeric antigen receptor and a prodrug converting enzyme.

## Claims

### Claim 1

A method for preparing immune cells for cancer therapy, comprising isolating immune cells from a donor subject, transducing the immune cells with
(a) a nucleic acid that encodes a first prodrug converting enzyme, wherein the first prodrug converting enzyme is expressed in the cytoplasm of the immune cell; and
optionally,
(b) a nucleic acid that encodes (i) a second prodrug converting enzyme, wherein the second prodrug converting enzyme is expressed on the surface of the immune cell or is secreted and/or (ii) a nucleic acid that encodes a receptor that binds to a target antigen and/or a nucleic acid encoding the receptor.

### Claim 2

A compound of Formula I
or a zwitterion, pharmaceutically acceptable salt, and/or solvate thereof, wherein
X is O or NH;
X2 is N or CH;
X3 is OH or H;
W1 is H or NH—R3;
two of R1, R2, and R3 are H and the remaining R1, R2, and R3 is
X4 and X5 are each independently O or NH;
X6 is O, NH, CH2, or C(Me)2;
R4, R5, R6, R7, and R8 are each independently H, —(CH2)3—NH(NH)—NH2, —(CH2)3—NH2, —(CH2)4—NH2, —CH2—C(O)OR13a, —(CH2)2—C(O)OR13b,
and
R9, R10, R11, R12, R13, R13a, and R13b are each independently alkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, —CH2—OC(O)-alkyl, —CH2—OC(O)-aryl, —CH2—OC(O)-heteroaryl, —CH2—OC(O)-aralkyl, or —CH2—OC(O)-heteroaralkyl.

### Claim 3

A compound of Formula II
or a zwitterion, pharmaceutically acceptable salt, and/or solvate thereof, wherein
X7 and X8 are each independently Cl, Br, I, O—S(O)2CH3, or O—S(O)2-tolyl;
X9 is —C(O)—O, —C(O)—NH, O, or NH;
R14 is a bond, alkylene, arylene, aralkylene, heteroarylene, or heteroaralkylene;
R15 is
X10 and X11 are each independently O or NH;
X6 is O, NH, CH2, or C(Me)2;
X12 is O, NH, CH2, or C(Me)2;
R16, R17, R18, R19, and R20 are each independently H, —(CH2)3—NH(NH)—NH2, —(CH2)3—NH2, —(CH2)4—NH2, —CH2—C(O)OR25a, —(CH2)2—C(O)OR25b,
and
R21, R22, R23, R24, R25, R25a, and R25b are each independently alkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, —CH2—OC(O)-alkyl, —CH2—OC(O)-aryl, —CH2—OC(O)-heteroaryl, —CH2—OC(O)-aralkyl, or —CH2—OC(O)-heteroaralkyl, provided that R21, R22, R23, R24, R25, R25a, and R25B are each independently not tert-butyl.

### Claim 4

A compounds of Formula III
or a zwitterion, pharmaceutically acceptable salt, and/or solvate thereof, wherein
R55 is
X35 and X36 are each independently O or NH;
X37 is O, NH, CH2, or C(Me)2;
R56, R57, R58, R59, and R60 are each independently H, —(CH2)3—NH(NH)—NH2, —(CH2)3—NH2, —(CH2)4—NH2, —CH2—C(O)OR6a, (CH2)2—C(O)OR65,
and
R61, R62, R63, R64, R65, R65a, and R65b are each independently alkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, —CH2—OC(O)-alkyl, —CH2—OC(O)-aryl, —CH2—OC(O)-heteroaryl, —CH2—OC(O)-aralkyl, or —CH2—OC(O)-heteroaralkyl.

### Claim 5

A compound that is
or a zwitterion, pharmaceutically acceptable salt, and/or solvate thereof.
